- Accession Number:
- Form Type:
- Zero Holdings:
- Publication Time:
- 2018-12-18 16:06:15
- Reporting Period:
- Accepted Time:
- 2018-12-18 16:06:15
- SEC Url:
- Form 4 Filing
|Cik||Name||Symbol||Sector (SIC)||IRS No|
|1012477||Avadel Pharmaceuticals Plc||FLML||Pharmaceutical Preparations (2834)||000000000|
|Cik||Name||Reported Address||Insider Title||Director||Officer||Large Shareholder||Other|
|1461953||F Michael Kanan||Block 10-1, Blanchardstown |
Corporate Park, Ballycoolin
Dublin L2 15
Reported Non-Derivative Transactions
|Sec. Name||Acquisiton - Disposition||Date||Amount||Price||Remaning Holdings||Equity Swap Involved||Form Type||Code||Nature of Ownership||Explanation|
|Equity Swap Involved||Form Type||Code||Nature of Ownership||Explanation|
Reported Derivative Holdings
|Sec. Name||Sec. Type||Price||Date||Expiration Date||Amount||Remaning Holdings||Nature of Ownership|
|Adss||Stock Option (right to buy)||$16.21||2025-10-28||100,000||100,000||Direct|
|Adss||Stock Option (right to buy)||$10.40||2026-12-14||100,000||100,000||Direct|
|Adss||Stock Option (right to buy)||$8.95||2027-12-12||80,000||80,000||Direct|
|Expiration Date||Amount||Remaning Holdings||Nature of Ownership|
- The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts.
- On December 14, 2018, the reporting person sold 8,429 ADSs in connection with the payment of certain withholding taxes related to the vesting of restricted ADSs that were granted to the reporting person on December 14, 2016 (such grant was reported by the reporting person on a Form 4 filed on December 16, 2016).
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.4732 to $2.64, inclusive. The reporting person undertakes to provide to Avadel Pharmaceuticals plc, any security holder of Avadel Pharmaceuticals plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3).
- Includes (a) 18,000 ADSs granted under the issuer's "Free Share" award program as restricted ADSs on 12/14/2016, all of which were issued to the reporting person on the second anniversary of the grant date; in connection with the payment of certain withholding taxes related to such issuance, the reporting person sold 8,429 ADSs on December 14, 2018; and (b) 18,000 restricted shares granted under the issuer's Omnibus Incentive Compensation Plan on 12/12/2017, under which 12,000 ADSs will vest and be issued on the second anniversary of the grant date and the remaining 6,000 ADSs will vest and be issued on the third anniversary of the grant date (with vesting of these restricted shares subject to the reporting person remaining in continuous service until the applicable anniversary of the date of grant).
- Options become exercisable as to 25,000 ADSs on each of the first four anniversaries after the 10/28/2015 grant date.
- Options become exercisable as to 25,000 ADSs on each of the first four anniversaries after the 12/14/2016 grant date.
- Options become exercisable as to 20,000 ADSs on each of the first four anniversaries after the 12/12/2017 grant date.